Cytokinetics, Inc. (CYTK)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.
The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy.
The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial.
Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
|IPO Date||Apr 29, 2004|
280 E Grand Ave
South San Francisco, California 94080-4808
|Phone||650 624 3000|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Robert I. Blum||Chief Executive Officer, President and Director|
|Ching W. Jaw||Senior Vice President and Chief Financial Officer|
|Dr. Fady Ibraham Malik FACC, M.D., Ph.D.||Executive Vice President of Research & Development|
|Andrew M. Callos||Executive Vice President and Chief Commercial Officer|
|Dr. James A. Spudich Ph.D.||Co-Founder and Member of Scientific Advisory Board|
|Jeff Lotz||Vice President of Sales and Operations|
|Robert C. Wong||Vice President and Chief Accounting Officer|
|David W. Cragg||Chief Human Resources and Administrative Officer|
|Joanna Siegall||Associate Director of Corporate Communications and Investor Relations|
|Kari K. Loeser J.D.||Vice President and Chief Compliance Officer|
Latest SEC Filings
|Jun 24, 2022||8-K||Current report|
|Jun 17, 2022||4||Statement of changes in beneficial ownership of securities|
|Jun 17, 2022||8-K||Current report|
|Jun 16, 2022||8-K||Current report|
|Jun 13, 2022||8-K||Current report|
|Jun 10, 2022||4||Statement of changes in beneficial ownership of securities|
|Jun 8, 2022||4||Statement of changes in beneficial ownership of securities|
|May 31, 2022||S-8||Securities to be offered to employees in employee benefit plans|
|May 27, 2022||8-K||Current report|
|May 23, 2022||8-K||Current report|